<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title42.html">
                                    Title 42
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/42CFR405.html">Part 405
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 405.517  Payment for drugs and biologicals that are not paid on
                            </h3>
                            <p class="depth1"><em>(a)</em> Applicability--</p><p class="depth2"><em>(1)</em> Payment for drugs and biologicals before  January 1, 2004. Payment for a drug or biological that is not paid on a  cost or prospective payment basis is determined by the standard  methodology described in paragraph (b) of this section. Examples of when  this procedure applies include a drug or biological furnished incident  to a physician's service, a drug or biological furnished by an  independent dialysis facility that is not included in the ESRD composite  rate set forth in Sec. 413.170(c) of this chapter, and a drug or  biological furnished as part of the durable medical equipment benefit.</p><p class="depth2"><em>(2)</em> Payment for drugs and biologicals on or after January 1, 2004.  Effective January 1, 2004, payment for drugs and biologicals that are  not paid on a cost or prospective payment basis are paid in accordance  with part 414, subpart I of this chapter.</p><p class="depth2"><em>(3)</em> Payment for drugs and biologicals on or after January 1, 2005.  Effective January 1, 2005, payment for drugs and biologicals that are  not paid on a cost or prospective payment basis are paid in accordance  with part 414, subpart K of this chapter.</p><p class="depth1"><em>(b)</em> Methodology. Payment for a drug or biological described in  paragraph (a) of this section is based on the lower of the actual charge  on the Medicare claim for benefits or 95 percent of the national average  wholesale price of the drug or biological.</p><p class="depth1"><em>(c)</em> Multiple-source drugs. For multiple-source drugs and  biologicals, for purposes of this regulation, the average wholesale  price is defined as the lesser of the median average wholesale price for  all sources of the generic forms of the drug or biological or the lowest  average wholesale price of the brand name forms of the drug or  biological.  [63 FR 58905, Nov. 2, 1998, as amended at 69 FR 1116, Jan. 7, 2004; 69  FR 66420, Nov. 15, 2004]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
